By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



39, rue du Bois Chaland

Evry Cedex    91029  France
Phone: 33-1-608-72600 Fax: 33-1-608-61609



Company News
Ipsen (IPN.PA) Presents Its New Strategy And Improved 2020 Financial Targets 5/11/2017 7:07:58 AM
Ipsen (IPN.PA) Completes Acquisition Of Select Consumer Healthcare Products From Sanofi (SNY) 5/8/2017 6:31:59 AM
Ipsen (IPN.PA) Reports Strong First Quarter 2017 Sales Growth Of 19,1% 4/27/2017 5:58:23 AM
Resolutions Submitted To Ipsen (IPN.PA)’s Shareholders' Meeting On June 7, 2017 4/25/2017 11:47:05 AM
Ipsen (IPN.PA) Announces Five Poster Presentations Of Dysport (Abobotulinumtoxina) Data At The 2017 Annual Meeting Of American Academy of Neurology 4/19/2017 8:46:06 AM
Ipsen (IPN.PA) Appoints Dr. Alexandre Lebeaut As Executive Vice-President, R&D, And Chief Scientific Officer 4/14/2017 6:04:51 AM
Ipsen (IPN.PA) Completes Acquisition Of ONIVYDE (Irinotecan Liposome Injection) And Additional Oncology Assets From Merrimack (MACK) 4/3/2017 11:27:41 AM
Merrimack (MACK) Stockholders Approve Sale Of ONIVYDE And Generic Version Of DOXIL To Ipsen (IPN.PA) For Up To $1.025 Billion 3/31/2017 7:30:21 AM
Ipsen (IPN.PA) Joins National Pharmaceutical Council 3/28/2017 11:53:37 AM
Ipsen (IPN.PA) Release: Blazing New Trails: Updates In The Care Of Children With Cerebral Palsy 3/21/2017 6:35:24 AM